Events

 This course provides a yearly comprehensive review of the field of cerebrovascular disease and covers epidemiology, diagnosis, acute management, secondary prevention, and rehabilitation. This educational activity is primarily targeted at neurologists, neurosurgeons, interventional neuroradiologists, cardiologists, primary care physicians, and emergency department physicians. Stroke team members, including nurse practitioners, nurses, physician assistants, and other providers treating stroke patients,will also benefit from this conference. At the conclusion of this activity, participants will be better able to: 1. Recognize modern advances in the diagnosis and management of small vessel cerebrovascular disease. 2. Examine the epidemiology, pathophysiology, and optimal diagnostic studies and treatments for stroke in young patients. 3. Analyze recent advances for the treatment of cerebral venous thrombosis with a focus on direct oral anticoagulants and endovascular therapies. 4. Describe different acute treatment options for patients with minor ischemic stroke, particularly dual antiplatelet therapy and intravenous thrombolysis. 5. Discuss the various evidence-based treatment options for the management of ischemic stroke due to intracranial atherosclerosis. VIEW AGENDA

The speakers are Xiaohui Lin (Zha Lab) and Alina Vaitsiankova (Ciccia Lab).

Program Overview VIRTUAL CONFERENCE Columbia University Irving Medical Center invites you to join the leading educators from Columbia University, addressing an overview of high yield challenging scenarios in the management of AL Amyloidosis. Through a combination of lectures and case-based presentations, this course will deliver up-to-date and cutting-edge information that can be directly integrated into clinical practice. Learning Objectives -Discuss the diverse clinical presentations and symptoms associated with AL amyloidosis. -Differentiate between the various organ involvements and their impact on the overall disease course. -Summarize the diagnostic approaches for evaluating kidney involvement in AL amyloidosis. -Evaluate the implications of renal dysfunction on disease prognosis and treatment decisions. -Identify the cardiac manifestations of AL amyloidosis. -Understand the diagnostic modalities for assessing cardiac involvement and the impact on patient outcomes. -Summarize the current therapeutic options for AL amyloidosis, including chemotherapy, plasma cell (anti-CD38) therapy and immunomodulatory agents. -Explore emerging therapies and novel approaches in the treatment of refractory AL amyloidosis. Accreditation Statement In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Columbia University. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Amedco Joint Accreditation #4008163. Physicians (ACCME) Credit Designation Statement Amedco LLC designates this live virtual activity for a maximum of 4.5 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physician Assistants PAs may claim a maximum of 4.5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit from organizations accredited by ACCME or a recognized state medical society. Nurse Practitioners The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit. Maximum of 4.5 hours.

J. William Harbour, MD  Professor and Chair, Department of Ophthalmology  The David Bruton, Jr. Chair in Ophthalmology  Member of Simmons Comprehensive Cancer Center  University of Texas Southwestern Medical Center